• Dabigatran in Advanced Thrombin Inhibition: Beyond the Bench

  2026-05-29

  Explore Dabigatran’s unique role in anticoagulation research, including its mechanistic precision and emerging applications in complex coagulation studies. Learn how this direct thrombin inhibitor surpasses conventional benchmarks for stroke and thrombosis research.

• Diclofenac: Non-Selective COX Inhibitor in Intestinal Organo

  2026-05-29

  Diclofenac empowers inflammation and pain signaling research with unmatched purity and workflow reliability, especially in hiPSC-derived intestinal organoid models. This guide distills advanced protocol tips, troubleshooting, and comparative insights that enable reproducible cyclooxygenase inhibition assays for anti-inflammatory drug research.

• High-Throughput Nanovial Screening Reveals MAIT and iNKT TCR

  2026-05-28

  The reference study presents a nanovial-based platform for high-throughput functional screening of unconventional T cell receptors (TCRs), enabling direct association of TCR identity with antigen-specific phenotype. This approach accelerates discovery of MAIT and iNKT cell TCRs with therapeutic potential in cancer immunotherapy.

• HyperScript™ Reverse Transcriptase: Advancing cDNA Synthesis

  2026-05-28

  HyperScript™ Reverse Transcriptase by APExBIO redefines RNA to cDNA conversion, empowering high-fidelity synthesis even from structured or low-abundance RNA templates. This guide connects core research needs with actionable workflows, troubleshooting insights, and critical innovations for qPCR-driven transcriptomics.

• Bivalent mRNA Vaccine RQ3025 Broadly Neutralizes SARS-CoV-2

  2026-05-27

  This study introduces the bivalent mRNA vaccine RQ3025, engineered to induce broad-spectrum neutralizing antibodies against diverse SARS-CoV-2 variants in preclinical models. The research demonstrates RQ3025’s immunogenicity, Th1-skewed cellular response, and safety profile, highlighting its potential for future clinical application against evolving viral threats.

• PINK1/Park2 Mitophagy Pathway Alleviates NAFLD: Mechanistic

  2026-05-27

  This study establishes that enhancing Park2-mediated mitophagy reverses mitochondrial damage and lipid accumulation in non-alcoholic fatty liver disease (NAFLD) models. By dissecting the PINK1/Park2 axis, the research identifies mitophagy as a therapeutic target in NAFLD, with technical implications for disease modeling and molecular workflow optimization.

• Tunable Human Intestinal Organoids: Balancing Renewal and Di

  2026-05-26

  This study introduces a tunable human intestinal organoid system that achieves a controlled balance between adult stem cell self-renewal and differentiation using targeted small molecule pathway modulators. The optimized culture method enhances cellular diversity and proliferative capacity, advancing organoid research utility for high-throughput and translational applications.

• Charge-Reversed Exosomes Enable Deep Cartilage mRNA Delivery

  2026-05-26

  Zhang et al. introduce charge-reversed cationic exosomes engineered to overcome the electrostatic and structural barriers of cartilage for targeted mRNA delivery in osteoarthritis. Their strategy allows efficient, non-viral gene transfer to chondrocytes in deep cartilage layers, paving the way for improved localized gene therapies for degenerative joint diseases.

• Bufalin as a Molecular Glue: New Horizons for Cancer Researc

  2026-05-25

  Explore the emerging role of Bufalin, a cardiotonic steroid, as a molecular glue degrader in cancer research. This article uncovers advanced mechanistic insights and practical assay guidance that set Bufalin apart in triple-negative breast cancer and hepatocellular carcinoma studies.

• HSBP7-Mediated Rescue in Titin Cardiomyopathy via Morphologi

  2026-05-25

  This study introduces a high-content morphological profiling assay to systematically investigate cardiomyocyte responses to gene perturbations associated with dilated cardiomyopathy. The authors identify HSBP7 deletion as a novel modulator that rescues contractile dysfunction in titin-mutant cardiomyocytes, opening new avenues for mechanistic heart failure research.

• CDK9 Inhibitor (A3294): Technical Application and Protocol G

  2026-05-24

  CDK9 inhibitor (A3294) provides researchers with a selective tool for inhibiting cyclin dependent kinase 9 activity, supporting studies in transcription elongation regulation and HIV-1 propagation inhibition. It is not suitable for protocols requiring broad-spectrum CDK inhibition or long-term storage of working solutions.

• SNORA38B Drives NSCLC Progression and Immunotherapy Resistan

  2026-05-23

  The referenced study identifies SNORA38B as a key oncogenic small nucleolar RNA in non-small cell lung cancer (NSCLC), showing that its high expression promotes tumor growth and suppresses immune responses via the GAB2/AKT/mTOR pathway. Targeting SNORA38B not only reduces tumorigenesis but also enhances the efficacy of immune checkpoint blockade, highlighting a promising therapeutic target and biomarker for NSCLC.

• TH287 MTH1 Inhibitor: A Strategic Lever for Radiosensitizing

  2026-05-22

  Explore how TH287, a potent MTH1 inhibitor, provides translational researchers with a precision tool to induce selective DNA damage and enhance the radiosensitivity of castration-resistant prostate cancer (CRPC) cells. This thought-leadership article synthesizes mechanistic insights, recent experimental breakthroughs, and strategic guidance for integrating TH287 into advanced oncology workflows—while positioning APExBIO's TH287 as a best-in-class solution.

• Actinomycin D in Translational Neuroscience: Mechanism to St

  2026-05-22

  This thought-leadership article explores how the mechanistic properties of Actinomycin D (ActD) empower translational researchers to dissect gene regulatory networks, with a special focus on neural development and apoptosis induction. By weaving together biological rationale, advanced protocol guidance, and recent breakthroughs in neuroepigenetics, the article delivers actionable insights for cancer and neuroscience innovators. It leverages both primary literature and expert product intelligence from APExBIO to offer a visionary roadmap for experimental design, reproducibility, and strategic impact.

• Murine RNase Inhibitor: Precision RNA Protection in Advanced

  2026-05-21

  Murine RNase Inhibitor from APExBIO delivers oxidation-resistant, high-specificity RNA protection for critical applications like real-time RT-PCR and cDNA synthesis, outperforming human-derived alternatives in challenging low-DTT setups. This guide details applied protocols, troubleshooting, and data-driven integration strategies for sensitive RNA workflows.

16425 records 1/1095 page Next 12345 下5页 Last page